Compare Merck & Co., Inc. (MRK) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Teradyne, Inc. — how do they compare? Merck & Co., Inc. trades at $141.84 (market cap $352.29B), while Teradyne, Inc. trades at $407.38 (market cap $64.38B). The key difference: Merck & Co., Inc. is far larger — about 5.5× Teradyne, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Teradyne, Inc. for 37 Days on average.
| MRK | TER | |
|---|---|---|
Market Cap | $352.29B | $64.38B |
Volume | 6,348,796 | 2,394,954 |
Sector | Health | Technology |
52-Week High | $156.43 | $483.84 |
52-Week Low | $82.49 | $132.05 |
Typical Hold Time | 98 Days | 37 Days |
Enterprise Value | $399.05B | $64.12B |
Dividend Yield | 2.38% | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Teradyne (TER) trades at $398.72, down 7.34% over 24 hours, but maintains strong technical support near $399. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and expanding AI-driven test portfolio through new products like Magnum E2 and Iris 100. Revenue growth is projected to accelerate from $3.19B in 2025 to $4.5B in 2026, with net income margin improving to 25.76%.
Outlook remains positive with 61% analyst buy ratings and $461.50 consensus price target, representing 16% upside. Key risks include semiconductor cycle volatility and competitive pressure from KLAC & COHU. Institutional accumulation continues with recent purchases by Envestnet and Nykredit, supporting bullish sentiment despite insider selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
